HDL as a biomarker, potential therapeutic target, and therapy
- PMID: 19940234
- PMCID: PMC2780869
- DOI: 10.2337/db09-0538
HDL as a biomarker, potential therapeutic target, and therapy
Figures
References
-
- Navab M, Berliner JA, Watson AD, Hama SY, Territo MC, Lusis AJ, Shih DM, Van Lenten BJ, Frank JS, Demer LL, Edwards PA, Fogelman AM: The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831– 842 - PubMed
-
- Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM: HDL and the inflammatory responses induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 21: 481– 488 - PubMed
-
- Berliner JA, Watson AD: A role for oxidized phospholipids in atherosclerosis. N Engl J Med 2005; 353: 9– 11 - PubMed
-
- Navab M, Imes SS, Hama SY, Hough GP, Ross LA, Bork RW, Valente AJ, Berliner JA, Drinkwater DC, Laks H: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991; 88: 2039– 2046 - PMC - PubMed
-
- Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758– 2767 - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
